Search research articles
Contact Us
Filters
Showing results (41-50 of 103) with videos related to
Page
of 11
Sort By:
Blood
|
August 23, 2019
Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation
Samuel A Stoner, Ming Yan, Katherine Tin Heng Liu, et al.
Cancers
|
December 26, 2018
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
Natalie Galanina, Rafael Bejar, Michael Choi, et al.
Blood Advances
|
October 7, 2022
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS
Yi-Jou Huang, Jia-Yu Chen, Ming Yan, et al.
Leukemia Research
|
June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.
The Journal of Clinical Investigation
|
January 3, 2020
X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation
Vijay G Sankaran, Jacob C Ulirsch, Vassili Tchaikovskii, et al.
Cancer Cell
|
September 23, 2014
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS
Rebekka K Schneider, Vera Ademà, Dirk Heckl, et al.
Haematologica
|
March 9, 2019
Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling
Daniel A Pollyea, Chelsea Harris, Jennifer L Rabe, et al.
Leukemia Research Reports
|
June 6, 2022
Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
David A Sallman, Rafael Bejar, Guillermo Montalban-Bravo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
Rafael Bejar, Kristen E Stevenson, Bennett A Caughey, et al.
The Journal of Clinical Investigation
|
February 24, 2015
X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation
Vijay G Sankaran, Jacob C Ulirsch, Vassili Tchaikovskii, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 103) with videos related to
Sort By:
Page
of 11
Blood
|
August 23, 2019
Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation
Samuel A Stoner, Ming Yan, Katherine Tin Heng Liu, et al.
Cancers
|
December 26, 2018
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
Natalie Galanina, Rafael Bejar, Michael Choi, et al.
Blood Advances
|
October 7, 2022
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS
Yi-Jou Huang, Jia-Yu Chen, Ming Yan, et al.
Leukemia Research
|
June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.
The Journal of Clinical Investigation
|
January 3, 2020
X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation
Vijay G Sankaran, Jacob C Ulirsch, Vassili Tchaikovskii, et al.
Cancer Cell
|
September 23, 2014
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS
Rebekka K Schneider, Vera Ademà, Dirk Heckl, et al.
Haematologica
|
March 9, 2019
Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling
Daniel A Pollyea, Chelsea Harris, Jennifer L Rabe, et al.
Leukemia Research Reports
|
June 6, 2022
Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
David A Sallman, Rafael Bejar, Guillermo Montalban-Bravo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
Rafael Bejar, Kristen E Stevenson, Bennett A Caughey, et al.
The Journal of Clinical Investigation
|
February 24, 2015
X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation
Vijay G Sankaran, Jacob C Ulirsch, Vassili Tchaikovskii, et al.
Page
of 11